Results in line with our objectives
Executive Vice President Finance
The results from 2019-2020 are solid and in line with our objectives, with revenue of €4.7 billion—up 1.6% at real exchange rates on the previous year. Sales rose in brand-name medicines (up 2.9% in terms of the number of boxes distributed) and generic medicines (up 5.3%). The growth in brand-name medicines was driven primarily by strong performance in oncology (up 12.8%), with Onivyde®, Oncaspar® and Lonsurf® achieving very positive results. This progress confirms the Group’s ambition to position itself as an innovative and recognized player in this field. EBITDA came out at €626 million, up 20.9% on the previous year, in part as a result of the controlled investments made as a result of the prevailing health and economic situation. These results for financial year 2019/2020 demonstrate our ongoing commitment to therapeutic progress to serve patient needs.